COMMUNICATION: Every client is an individual, and it is not possible to determine in advance how your system will react to the treatment. It is sometimes necessary to adjust your program as we proceed. It is your responsibility to do your part by following healthy dietary guidelines, exercise your body and make necessary behavioural modifications.
1. Alternatives to Ozempic therapy are surgical procedures, oral medical treatments (including Orlistat) and / or dietary and lifestyle changes alone. 2. Several weeks to months of treatment may be required depending on your individual response. 3. If a missed dose is more than 5 days late, the missed dose should not be taken, and the next dose should be taken at the normal time. 4. It is essential to combine eating, exercise and behavioural modifications with Ozempic. 5. Ozempic should not be used in combination with another GLP-1 receptor agonist, insulin or insulin secretagogues (such as sulfonylureas) due to the risk of hypoglycaemia. 6. Upon initiation of Ozempic treatment in patients on warfarin or other coumarin derivatives more frequent monitoring of International Normalised Ratio (INR) is recommended. 7. Ozempic causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor for potential consequences of delayed absorption of oral medications concomitantly administered with Ozempic
8. There are several special warnings and precautions for use of Ozempic including warnings on pancreatitis, cholelithiasis and cholecystitis, thyroid disease, heart rate, dehydration and hypoglycaemia in people with type 2 diabetes.
Thyroid adverse events, such as goitre have been reported in particular in patients with pre-existing thyroid disease. Ozempic should therefore be used with caution in patients with thyroid disease.
A higher rate of cholelithiasis and cholecystitis (gallstone and gallbladder disease) has been observed in patients treated with semaglutide. Cholelithiasis and cholecystitis may lead to hospitalisation and cholecystectomy (surgery to remove the gallbladder Patients should be aware of the characteristic symptoms of cholelithiasis and cholecystitis.
11. Signs and symptoms of dehydration, including renal impairment and acute renal failure, have been reported in patients treated with Semaglutide. Patients treated with semaglutide should be advised of the potential risk of dehydration in relation to gastrointestinal side effects and take precautions to avoid fluid depletion. Patients should also be aware of the symptoms of increased heart rate.
Acute pancreatitis has been observed with the use of Semaglutide. Patients and their carers should be told how to recognise signs and symptoms of acute pancreatitis and advised to seek immediate medical attention if symptoms develop. If pancreatitis is suspected, semaglutide should be discontinued; if acute pancreatitis is confirmed, semaglutide should not be restarted.
13. Ozempic may cause dose-dependent and Itreatment-duration-dependent thyroid C-cell tumours at clinically relevant exposures in both genders of rats and mice. It is unknown whether Ozempic causes thyroid C-cell tumours, including medullary thyroid carcinoma (cancer, MTC), in humans, as the human relevance of semaglutide-induced rodent thyroid C-cell tumours has not been determined. Patients should be aware of symptoms of thyroid tumours (such as a mass in the neck, difficulty swallowing, difficulty breathing or shortness of breath, persistent hoarseness